376 related articles for article (PubMed ID: 25351456)
1. Brief versions of the FACIT-fatigue and FAACT subscales for patients with non-small cell lung cancer cachexia.
Salsman JM; Beaumont JL; Wortman K; Yan Y; Friend J; Cella D
Support Care Cancer; 2015 May; 23(5):1355-64. PubMed ID: 25351456
[TBL] [Abstract][Full Text] [Related]
2. ROMANA 3: a phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia.
Currow D; Temel JS; Abernethy A; Milanowski J; Friend J; Fearon KC
Ann Oncol; 2017 Aug; 28(8):1949-1956. PubMed ID: 28472437
[TBL] [Abstract][Full Text] [Related]
3. Anamorelin hydrochloride for the treatment of cancer-anorexia-cachexia in NSCLC.
Zhang H; Garcia JM
Expert Opin Pharmacother; 2015 Jun; 16(8):1245-53. PubMed ID: 25945893
[TBL] [Abstract][Full Text] [Related]
4. Validation and real-world assessment of the Functional Assessment of Anorexia-Cachexia Therapy (FAACT) scale in patients with advanced non-small cell lung cancer and the cancer anorexia-cachexia syndrome (CACS).
LeBlanc TW; Samsa GP; Wolf SP; Locke SC; Cella DF; Abernethy AP
Support Care Cancer; 2015 Aug; 23(8):2341-7. PubMed ID: 25586527
[TBL] [Abstract][Full Text] [Related]
5. Mapping health-related quality of life scores from FACT-G, FAACT, and FACIT-F onto preference-based EQ-5D-5L utilities in non-small cell lung cancer cachexia.
Meregaglia M; Borsoi L; Cairns J; Tarricone R
Eur J Health Econ; 2019 Mar; 20(2):181-193. PubMed ID: 28948436
[TBL] [Abstract][Full Text] [Related]
6. Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials.
Temel JS; Abernethy AP; Currow DC; Friend J; Duus EM; Yan Y; Fearon KC
Lancet Oncol; 2016 Apr; 17(4):519-531. PubMed ID: 26906526
[TBL] [Abstract][Full Text] [Related]
7. Anamorelin (ONO-7643) for the treatment of patients with non-small cell lung cancer and cachexia: Results from a randomized, double-blind, placebo-controlled, multicenter study of Japanese patients (ONO-7643-04).
Katakami N; Uchino J; Yokoyama T; Naito T; Kondo M; Yamada K; Kitajima H; Yoshimori K; Sato K; Saito H; Aoe K; Tsuji T; Takiguchi Y; Takayama K; Komura N; Takiguchi T; Eguchi K
Cancer; 2018 Feb; 124(3):606-616. PubMed ID: 29205286
[TBL] [Abstract][Full Text] [Related]
8. Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials.
Garcia JM; Boccia RV; Graham CD; Yan Y; Duus EM; Allen S; Friend J
Lancet Oncol; 2015 Jan; 16(1):108-16. PubMed ID: 25524795
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive validation of the functional assessment of anorexia/cachexia therapy (FAACT) anorexia/cachexia subscale (A/CS) in lung cancer patients with involuntary weight loss.
Gelhorn HL; Gries KS; Speck RM; Duus EM; Bourne RK; Aggarwal D; Cella D
Qual Life Res; 2019 Jun; 28(6):1641-1653. PubMed ID: 30796591
[TBL] [Abstract][Full Text] [Related]
10. Anamorelin (ONO-7643) in Japanese patients with non-small cell lung cancer and cachexia: results of a randomized phase 2 trial.
Takayama K; Katakami N; Yokoyama T; Atagi S; Yoshimori K; Kagamu H; Saito H; Takiguchi Y; Aoe K; Koyama A; Komura N; Eguchi K
Support Care Cancer; 2016 Aug; 24(8):3495-505. PubMed ID: 27005463
[TBL] [Abstract][Full Text] [Related]
11. Anamorelin hydrochloride in the treatment of cancer anorexia-cachexia syndrome: design, development, and potential place in therapy.
Graf SA; Garcia JM
Drug Des Devel Ther; 2017; 11():2325-2331. PubMed ID: 28848326
[TBL] [Abstract][Full Text] [Related]
12. Anamorelin for advanced non-small-cell lung cancer with cachexia: Systematic review and meta-analysis.
Nishie K; Yamamoto S; Nagata C; Koizumi T; Hanaoka M
Lung Cancer; 2017 Oct; 112():25-34. PubMed ID: 29191597
[TBL] [Abstract][Full Text] [Related]
13. A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in patients with cancer cachexia and low body mass index.
Naito T; Uchino J; Kojima T; Matano Y; Minato K; Tanaka K; Mizukami T; Atagi S; Higashiguchi T; Muro K; Takayama K; Furuse J; Morishima E; Takiguchi T; Tamura K
Cancer; 2022 May; 128(10):2025-2035. PubMed ID: 35195274
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Anamorelin, a Novel Non-Peptide Ghrelin Analogue, in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) and Cachexia-Review and Expert Opinion.
Currow DC; Maddocks M; Cella D; Muscaritoli M
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30400622
[TBL] [Abstract][Full Text] [Related]
15. Anamorelin hydrochloride in the treatment of cancer anorexia-cachexia syndrome.
Currow DC; Abernethy AP
Future Oncol; 2014 Apr; 10(5):789-802. PubMed ID: 24472001
[TBL] [Abstract][Full Text] [Related]
16. Validation of the Chinese version of functional assessment of anorexia-cachexia therapy (FAACT) scale for measuring quality of life in cancer patients with cachexia.
Zhou T; Yang K; Thapa S; Fu Q; Jiang Y; Yu S
Support Care Cancer; 2017 Apr; 25(4):1183-1189. PubMed ID: 27900546
[TBL] [Abstract][Full Text] [Related]
17. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group.
; Strasser F; Luftner D; Possinger K; Ernst G; Ruhstaller T; Meissner W; Ko YD; Schnelle M; Reif M; Cerny T
J Clin Oncol; 2006 Jul; 24(21):3394-400. PubMed ID: 16849753
[TBL] [Abstract][Full Text] [Related]
18. Quality of life and anorexia/cachexia in lung cancer: validation of the Spanish version of the FAACT instrument.
Arrieta O; Luvián-Morales J; Turcott JG; Oñate-Ocaña LF
Qual Life Res; 2018 Oct; 27(10):2709-2718. PubMed ID: 29987501
[TBL] [Abstract][Full Text] [Related]
19. Re-validation and shortening of the Functional Assessment of Anorexia/Cachexia Therapy (FAACT) questionnaire.
Ribaudo JM; Cella D; Hahn EA; Lloyd SR; Tchekmedyian NS; Von Roenn J; Leslie WT
Qual Life Res; 2000; 9(10):1137-46. PubMed ID: 11401046
[TBL] [Abstract][Full Text] [Related]
20. FAACT-Anorexia Cachexia Scale: Cutoff Value for Anorexia Diagnosis in Advanced Non-Small Cell Lung Cancer Patients.
Turcott JG; Oñate-Ocaña LF; Soca-Chafre G; Ramírez-Tirado LA; Flores-Estrada D; Zatarain-Barrón ZL; Arrieta O
Nutr Cancer; 2019; 71(3):409-417. PubMed ID: 30273069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
